CNBX Pharmaceuticals Inc (CNBX)
0.013
0.00 (0.00%)
USD |
OTCM |
Apr 25, 16:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 0.4044M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -29.73% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | 0.5452 |
Price to Book Value | -- |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | -0.548 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 99.99% |
Profile
CNBX Pharmaceuticals Inc is a biotechnology company. It develops pharmaceuticals focusing on cancer research utilizing HTS technology and personalized bioinformatics tools. The company's main focus is the development of cannabinoid therapies and other technologies for the treatment of cancer, mainly cancers of the gastrointestinal tract, skin, breast, and prostate. The firm's main product is the RCC-33, an oral capsule for the treatment of colorectal cancer. The company tools include delivery systems, personalized medicine diagnostics, and therapies based on Cannabinoid compounds. |
URL | https://www.cnbxpharma.com |
Investor Relations URL | N/A |
HQ State/Province | Maryland |
Sector | Health Care |
Industry | Pharmaceuticals |
Equity Style | N/A |
Next Earnings Release | N/A |
Last Earnings Release | N/A |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
CNBX Pharmaceuticals Inc is a biotechnology company. It develops pharmaceuticals focusing on cancer research utilizing HTS technology and personalized bioinformatics tools. The company's main focus is the development of cannabinoid therapies and other technologies for the treatment of cancer, mainly cancers of the gastrointestinal tract, skin, breast, and prostate. The firm's main product is the RCC-33, an oral capsule for the treatment of colorectal cancer. The company tools include delivery systems, personalized medicine diagnostics, and therapies based on Cannabinoid compounds. |
URL | https://www.cnbxpharma.com |
Investor Relations URL | N/A |
HQ State/Province | Maryland |
Sector | Health Care |
Industry | Pharmaceuticals |
Equity Style | N/A |
Next Earnings Release | N/A |
Last Earnings Release | N/A |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |